Payan C, Kouyoudjiam S, Chennebault JM, Cogny F, Ifrah N, Pichard E, Lunel F; International Conference on AIDS.
Int Conf AIDS. 1998; 12: 535-6 (abstract no. 31202).
Laboraitoire de Virologie, Chu Angers 4, France.
OBJECTIVE: To analyse the short-term kinetics of cytomegalovirus (CMV) in patients after ganciclovir (GCV) treatment. METHODS: Peripheral white blood cells (WBC) of 10 HIV-infected patients (AIDS), 6 kidney (KT) and 2-bone marrow (BMT) transplant recipients were assessed by a CMV DNA quantitative system (HCS Murex kit), as previously described (Payan et al. J. Virol. Methods 1997). These WBC were recovered from the whole blood specimens of these patients every day up to 7 days and at days 10, 15, 20, 30 of GCV therapy. RESULTS: The medianes of initial CMV DNA (i) concentration in WBC, of viral half-life and turnover calculated from the viral curves obtained for each patients in each group are shown in the next table. TABULAR DATA, SEE ABSTRACT VOLUME. CMV half-life in WBC were twice longer in AIDS patients compared to transplant recipients, in relation with a twice higher concentration of initial CMV DNA (p = 0.001). On the contrary, the viral turnover was 3 to 5 times lower in AIDS patients. CONCLUSION: These half-lifes were similar to the one described for HIV producing cells (1.6 days, Perelson et al. Science 1996). But the CMV day turnover rate is much lower than the one of HIV (103 x 10(8) virus/day), especially in AIDS patients, due to the higher viral diversity of HIV compared to CMV. These kinetics demonstrate a higher efficiency of GCV in transplant recipients compared to AIDS patients suffering of CMV disease.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Bone Marrow Transplantation
- Cytomegalovirus
- Cytomegalovirus Infections
- Cytomegalovirus Retinitis
- Ganciclovir
- HIV Seropositivity
- Humans
- Kinetics
- Leukocytes
- Transplantation, Homologous
- pharmacokinetics
- surgery
- therapy
- transplantation
Other ID:
UI: 102229592
From Meeting Abstracts